Karen Bernstein - 16 Feb 2023 Form 4 Insider Report for Codiak BioSciences, Inc.

Role
Director
Signature
/s/ Yalonda Howze, Attorney-in-Fact for Karen Bernstein
Issuer symbol
N/A
Transactions as of
16 Feb 2023
Net transactions value
$0
Form type
4
Filing time
21 Feb 2023, 15:31:55 UTC
Previous filing
21 Jun 2022
Next filing
27 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise +8,750 8,750 16 Feb 2023 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Restricted Stock Units Options Exercise $0 -8,750 -100% $0.000000* 0 16 Feb 2023 Common Stock 8,750 See footnote F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 Held by The Karen Bernstein Trust, As Amended & Restated, of which the reporting person is a trustee.
F3 Each RSU represents a contingent right to receive one share of common stock.
F4 On February 16, 2022, the reporting person was granted 8,750 RSUs, which vested in full on February 16, 2023.